In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer, CRISPR form gene editing JV to cure blood disorders, blindness, and congenital heart disease

Executive Summary

Bayer HealthCare Pharmaceuticals AG and CRISPR Therapeutics formed a 50/50 joint venture tasked with finding cures for blood disorders (including hemophilia), blindness, and congenital heart disease. The Bayer LifeScience Center (BLSC), a new R&D innovation unit at Bayer, help set up the JV, which will focus on creating delivery systems for systemic administration of CRISPR-Cas9 technology.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Joint Venture
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies